Literature DB >> 11104558

Intra-arterial chemotherapy in locally advanced or recurrent carcinomas of the penis and anal canal: an active treatment modality with curative potential.

A D Roth1, C R Berney, S Rohner, A S Allal, P Morel, M C Marti, M S Aapro, P Alberto.   

Abstract

The prognosis of locally advanced or recurrent carcinomas of the penis (PE) and of the anal canal (AC) after conventional treatment is dismal. We report 16 patients (eight with AC carcinomas and eight with PE cancers) treated by intra-arterial (IA) chemotherapy. Fifteen of them were treated for locally advanced or recurrent disease and one in an adjuvant setting. The chemotherapy was administered via a femoral IA catheter with its tip located above the aortic bifurcation, under the inferior mesenteric artery. It consisted of eight push injections, given over a 48-h period, of the following drug combination: cisplatin 8.5 mg m(-2), 5-FU 275 mg m(-2), methotrexate 27.5 mg m(-2), mitomycin C 1.2 mg m(-2), and bleomycin 4 mg m(-2). Leucovorin was given po, 4 x 15 mg day(-1), during the chemotherapy and for 3 days thereafter. A total of 52 cycles of treatment were administered. Of the 15 patients evaluable for response, six obtained a CR (three PE, three AC) and eight a PR. Among the complete responders, four are alive and disease-free 2-15 years after treatment. The other patients enjoyed an objective response lasting 3-25 months (median 7 months). Four patients developed grade III/IV haematological toxicity with three episodes of febrile neutropenia, one of them with a fatal outcome due to patient's failure to obtain medical attention at the onset of his fever, one a grade III mucositis of the glans, and four a grade III/IV cutaneous toxicity, the latter caused by the IA administration of bleomycin. In conclusion, IA chemotherapy is effective and potentially curative in locoregionally advanced or recurrent carcinomas of the penis and of the anus. Its contribution in the primary management of advanced penile or anal carcinoma should be prospectively investigated. Copyright 2000 Cancer Research Campaign.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11104558      PMCID: PMC2363463          DOI: 10.1054/bjoc.2000.1525

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  7 in total

Review 1.  [Systemic therapy of penile cancer].

Authors:  E Preis; P Albers; G Jakse
Journal:  Urologe A       Date:  2006-05       Impact factor: 0.639

Review 2.  [Options in palliative therapy for penile cancer].

Authors:  E Preis; G Jakse
Journal:  Urologe A       Date:  2007-01       Impact factor: 0.639

3.  [Neoadjuvant and adjuvant chemotherapy in patients with advanced penile cancer].

Authors:  A Heidenreich; G Jakse
Journal:  Urologe A       Date:  2007-10       Impact factor: 0.639

Review 4.  Clinical scenarios for neoadjuvant chemotherapy of squamous penile cancer that is clinically node positive.

Authors:  Mayer N Fishman
Journal:  Transl Androl Urol       Date:  2017-10

5.  Intraarterial chemotherapy as the first-line therapy in penile cancer.

Authors:  P-H Chiang; C-H Chen; Y-C Shen
Journal:  Br J Cancer       Date:  2014-07-24       Impact factor: 7.640

6.  Resistant metastatic penile carcinoma and response to biochemotherapy with paclitaxel and epidermal growth factor receptor monoclonal antibody, nimotuzumab.

Authors:  Avinash Pandey; Vanita Noronha; Amit Joshi; Hemant Tongaonkar; Ganesh Bakshi; Kumar Prabhash
Journal:  Indian J Med Paediatr Oncol       Date:  2013-01

7.  Intraarterial chemotherapy with gemcitabine and cisplatin in locally advanced or recurrent penile squamous cell carcinoma.

Authors:  Jian-Ye Liu; Yong-Hong Li; Zhuo-Wei Liu; Zhi-Ling Zhang; Yun-Lin Ye; Kai Yao; Hui Han; Zi-Ke Qin; Fang-Jian Zhou
Journal:  Chin J Cancer       Date:  2013-05-14
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.